Table 2.
Interventions
| Total N = 185 | ATDW group n = 59 | ATC group n = 126 | P-value | |
|---|---|---|---|---|
| BFP sample Sputum BAL |
125 (67.6) 60 (32.4) |
41 (69.5) 18 (30.5) |
84 (66.7) 42 (33.3) |
.70 |
| Antibiotic use type Anti-MRSA Antipseudomonal Anti-atypical Ampicillin-sulbactam Ceftriaxone Other |
101 (54.6) 119 (64.3) 94 (50.8) 28 (15.1) 47 (25.4) 18 (9.7) |
17 (28.8) 21 (35.6) 16 (27.1) 6 (10.2) 9 (15.3) 0 |
84 (66.7) 98 (77.8) 78 (61.9) 22 (17.5) 38 (30.2) 18 (14.3) |
<.001 <.001 <.001 .20 .03 .002 |
| Duration of antibiotics, median (IQR), days Anti-MRSA Antipseudomonal Anti-atypical Ampicillin-sulbactam Ceftriaxone Other Total |
2 (1..95–2.659) 3 (.765–3.325) 2 (1.10–3.02.95) 1 (.325–2.877) 1 (1.00–2.548) NA 1 (.00–2.988) |
2 (1.549–4.215) 6 (3.81–9.23) 3 (2.01.95–5.04.97) 2 (.91–4.03.96) 4 (2.106–6.05.95) 2 (1.545–4.60) 7 (4.765–8.989) |
.042 <.001 .0545 .1875 .001 NA <.001 |
|
| Time to PCR from admission, median (days) | 1.8 (.9–3.1) | 2.3 (1.1–5.2) | 1.6 (.7–2.8) | <.001 |
| Time to PCR from development of PNA, median (days) | 1.2 (.6–2.0) | 1.3 (.8–2.3) | 1.1 (.5–1.9) | .19 |
| PCR turnaround time, median (days) | .8 (.5–1.0) | .9 (.6–1.2) | .8 (.4–1.0) | .02 |
| MRSA screening 1 | 140 (75.7) | 43 (72.9) | 97 (77.0) | .54 |
| Atypical Antigen Screening | 155 (83.8) | 44 (74.6) | 111 (88.1) | .02 |
| Blood Culture Collected | 155 (83.8) | 39 (66.1) | 116 (92.1) | <.001 |
| Sputum/BAL culture turnaround time, mean (days) | 2.5 (2.0–2.8) | 2.5 (2.0–2.9) | 2.5 (2.0–2.8) | .61 |
| De-escalation | NA | NA | 80 (63.5) | NA |
| De-escalation type Anti-MRSA Antipseudomonal Anti-atypical Other |
NA | NA | N = 80 54 (67.5) 20 (25.0) 40 (50.0) 8 (10.0) |
NA |
All data are represented as n (%) unless specified otherwise.
1
MRSA/MSSA nasal screening is done by culture with turnaround time of 36h and used to measure transmission and identify individuals at greater risk for invasive infections; 29/140 tests done by PCR